Georgios Skretas graduated from the School of Chemical Engineering of the National Technical University of Athens (Greece) in 1998 and received his PhD in Chemical and Biological Engineering from Princeton University (USA) in 2006. He then moved on to the University of Texas at Austin (USA) to carry out post-doctoral research under the guidance of Prof. George Georgiou. In 2010, he received a Marie Curie International Reintegration Fellowship to return back to Greece and the National Hellenic Research Foundation. Since then, Dr. Skretas has been Principal Investigator at the Institute of Chemical Biology, where he currently holds the rank of Research Associate Professor. He has recently been awarded with a Consolidator Grant by the European Research Council (ERC) to develop engineered bacteria that will function as a discovery platform for new drugs against diseases caused by protein misfolding and aggregation. Dr. Skretas is also Founder and Chief Executive Officer of ResQ Biotech, an early-stage drug discovery company established in 2019 at the Patras Science Park.